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Protocol
AbstrACt
Introduction Dementia is the fastest growing major 
cause of disability globally and may have a profound 
impact on the health-related quality of life (HRQoL) of both 
the patient with dementia and those who care for them. 
This review aims to systematically identify and synthesise 
the measurements of HRQoL for people with, and their 
caregivers across the full spectrum of, dementia from its 
preceding stage of predementia to end of life.
Methods and analysis A systematic literature review was 
conducted in Medical Literature Analysis and Retrieval System 
Online , ExcerptaMedicadataBASE, Cochrane Database of 
Systematic Reviews , Cochrane Central Register of Controlled 
Trials, Database of Abstracts of Reviews of Effect, National 
Health Service Economic Evaluation Database and PsycINFO 
between January 1990 and the end of April 2017. Two 
reviewers will independently assess each study for inclusion 
and disagreements will be resolved by a third reviewer. Data 
will be extracted using a predefined data extraction form 
following best practice. Study quality will be assessed with 
the Effective Public Health Practice Project quality assessment 
tool. HRQoL measurements will be presented separately for 
people with dementia and caregivers by instrument used and, 
when possible, HRQoL will be reported by disease type and 
stage of the disease. Descriptive statistics of the results will be 
provided. A narrative synthesis of studies will also be provided 
discussing differences in HRQoL measurements by instrument 
used to estimate it, type of dementia and disease severity.
Ethics and dissemination This systematic literature 
review is exempt from ethics approval because the work 
is carried out on published documents. The findings 
of the review will be disseminated in a related peer-
reviewed journal and presented at conferences. They will 
also contribute to the work developed in the Real World 
Outcomes across the Alzheimer’s disease spectrum for 
better care: multimodal data access platform (ROADMAP).
trial registration number CRD42017071416.
IntroduCtIon 
Dementia is a global disease with little prospect 
of a cure or means of preventing its progres-
sion. In 2014, it was estimated to affect 7.1% 
of people aged 65 and above worldwide.1 It 
is a debilitating neurodegenerative condition 
which causes a progressive and irreversible 
decline in cognitive, social and physical func-
tion. There are several types of dementia and 
some people may present with a combination 
of types. Alzheimer’s disease (AD) is the most 
common cause of dementia, accounting for 
60%–80% of all cases.2 Other causes include 
vascular dementia, frontotemporal dementia, 
dementia with Lewy bodies and others. Irre-
spective of the cause, dementia results in 
significant decline in intellectual abilities, 
such as memory and causes behavioural 
changes, insight and judgement, anxiety and 
depression, with eventual loss of physical 
functions and personality. This eventually 
becomes severe enough to interfere with a 
person’s daily functioning and activities of 
daily living.
The cognitive and functional decline associ-
ated with dementia has a profound impact on 
the health-related quality of life (HRQoL) of 
both the patient and those that care for them. 
HRQoL, defined as the way health is empiri-
cally estimated to affect QoL, is a multidimen-
sional concept that includes domains related 
strengths and limitations of this study
 ► This systematic literature review on quality of life 
of people with predementia and dementia and their 
caregivers is based on a detailed search strategy 
including studies from any country published in any 
language, covering the time frame from 1 January 
1990 until 28 April 2017.
 ► The review follows robust guidelines and the qual-
ity of the papers included will be assessed using a 
validated tool.
 ► The heterogeneity in the way quality of life is mea-
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to physical, mental, emotional and social functioning. 
HRQoL is now recognised as an increasingly valued 
health outcome measure in dementia. With no cure, the 
focus of attention in dementia care is to promote patient 
well-being and to maintain optimal HRQoL. As HRQoL 
refers to all aspects of a person’s life, it can provide valu-
able information on the patient’s self-perception of health 
and intervention impact. HRQoL measures attempt to 
evaluate directly the impact of dementia or interventions 
on people’s ability to function in life. They have therefore 
become a key way in which to assess the effectiveness of 
health and social service interventions.
Dementia patients require long-term care and support, 
and the responsibility for caregiving most often falls on 
informal caregivers including family members, friends 
and neighbours. These caregivers provide a valuable 
resource for patients with dementia. There are over 
700 000 informal caregivers of people with dementia 
estimated to be providing £12.4 billion of unpaid care 
in the UK per year.3 The work of these caregivers is 
vital to support the growing number of people affected 
by dementia and without them, the formal care system 
would likely collapse. The National Dementia Strategy for 
England4 recognises this and supporting caregivers is now 
a national and international policy priority.5
Given that caregivers of people with dementia are consid-
ered to be such an important resource, it is important to 
ensure that their own HRQoL is satisfactory. For many, 
the experience of caring for their loved ones provides 
personal satisfaction. However, the experience can also 
have a negative impact. Caregivers often have high levels 
of anxiety, stress and depression6 as caring for people with 
dementia often places a heavy mental, physical, financial 
and social burden on them.7–11 Great demands are placed 
on caregivers who are often elderly themselves.8 9 As a 
result, caregivers might find themselves neglecting their 
own health and HRQoL. This could ultimately impact on 
the quality of the care that they provide for people with 
dementia. Therefore, addressing caregivers’ HRQoL is an 
important challenge.
Shearer et al10 conducted a systematic review of the 
literature on health value states for AD patients and 
their caregivers based on generic preference-based 
instruments.10 Two recently published systematic reviews 
examined the factors associated with the HRQoL of 
dementia patients , either in all types of setting12 or in 
long-term care facilities in particular.13 A few reviews have 
identified HRQoL measures for dementia patients and 
their carers.14–16 Caregiver burden has also been explored 
in a few systematic reviews, either identifying factors 
constituting caregiver burden on informal caregivers of 
dementia  patients,7 exploring the role of self-efficacy in 
HRQoL of family carers of dementia patients,8 reviewing 
evidence for negative caregiver outcomes in mild cogni-
tive impairment (MCI)9 and synthesising risk factors or 
reviewing caregiver burden and interventions for familial 
caregivers of AD patients.11 However, apart from Shearer 
et al,10 none of these reviews report measurements for 
HRQoL of these patients or caregivers. Furthermore, 
Shearer et al10 did not consider dementia-specific HRQoL 
measures. This review therefore aims to address this gap 
in the literature by addressing the following questions:
1. What is the HRQoL for people with dementia across 
all stages of disease severity, from its preceding state of 
predementia (including preclinical AD—biomarker 
positive but presymptomatic, early symptoms, MCI or 
prodromal AD) through to diagnosed dementia and 
end of life?
2. What is the HRQoL for caregivers of people with de-
mentia across all stages of disease severity, from its 
preceding stage of predementia to end of life?
MEthods And AnAlysIs
Protocol and registration
The preparation of this protocol followed the reporting 
guidelines of the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis for Protocols 2015 (PRIS-
MA-P).17 A completed PRISMA-P checklist is available 
in online supplementary file 1. The protocol was regis-
tered with the PROSPERO international prospective 
register of systematic reviews (registration number 
CRD42017071416). The systematic review manuscript will 
be prepared following the PRISMA statement.18–20 In case 
of amendments to this protocol, they will be reported and 
published with the results of the review.
study selection criteria
Participants
The focus of this review is on adult populations reporting 
to have either predementia or dementia, irrespective of 
the type and stage of the disease and their caregivers. 
Our main interest is in AD, the most common cause 
of dementia, but given the lack of diagnostic accuracy 
and the recognised overlap between different causes of 
dementia, all causes will be considered.
Study design
This systematic literature review will include studies 
reporting measurements of HRQoL for adult onset 
predementia or dementia patients and their caregivers 
published in peer-reviewed journals or grey literature. We 
will only include primary studies that provide quantitative 
results. Qualitative studies will not be included.
The following study designs will be considered for inclu-
sion: experimental studies, quasiexperimental studies, 
observational studies (either prospective or retrospective) 
and register-based studies. In cases where multiple studies 
used the same patient cohort, we will use the data from 
the study that presented the most detailed information on 
HRQoL. Case studies, series of case studies, studies with 
sample size of 30 or less patients, trial protocols, phase 
I clinical trials, news articles, interviews that do not use 
a structured quantitative questionnaire, patient educa-
tion handouts, reviews, opinion or expert articles, edito-
rials, letters to the editor, authors and editor’s replies to 
comments will not be included.
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Modelling studies will be excluded but studies informing 
the model parameters will be considered for inclusion. 
Similarly, existing reviews of HRQoL of people with 
dementia and their caregivers will not be included but 
their reference lists will be screened for additional studies. 
Conference abstracts will not be included. However, the 
abstracts will be screened to determine whether the work 
presented has been published in a peer-reviewed journal 
or thesis. If this is the case, then the published study will 
be considered for inclusion.
Outcomes
The outcomes of interest are:
 ► The HRQoL of people with either predementia or 
dementia;
 ► The HRQoL of caregivers of people with either prede-
mentia or dementia.
Where possible, the HRQoL of people with dementia 
and their caregivers will be detailed by stage of the disease: 
preclinical dementia (biomarker positive but presympto-
matic), early symptoms (memory and other behavioural 
changes), MCI, prodromal AD, mild dementia, moderate 
dementia, severe dementia and end of life to understand 
how HRQoL evolves throughout disease progression.
Quality of life
A wide range of instruments have been developed to 
measure HRQoL. These include both generic and 
disease-specific instruments. Whereas generic HRQoL 
measures are universal and cover general health aspects, 
regardless of the presence of absence of a disease, 
disease-specific HRQoL measures target individual 
diseases and aim to emphasise the problems specific to 
patients with a specific disease, such as dementia. These 
generic and disease-specific instruments can be further 
subdivided into preference or non-preference depending 
on whether the index has been derived by using prefer-
ence weights obtained from patients or the general public 
or using simple summation of item scores.
In this review, we will include any study reporting a 
quantitative measurement of HRQoL, regardless of the 
instrument used to estimate it.
Intervention
All types of interventions related to dementia, either 
symptomatic or disease modifying, will be included. 
We will also include studies that have not assessed any 
intervention.
Language
No language restrictions were applied to the search.
Setting
No geography restrictions were applied to the search.
search strategy
Electronic databases
The selection of the electronic databases used was carried 
out with the assistance of an information specialist. 
The search terms were devised in conjunction with an 
information specialist based on the search strategy of a 
previous literature review.10 Medical Literature Analysis 
and Retrieval System Online, Excerpta Medica data-
BASE, Cochrane Database of Systematic Reviews, Central 
Register of Controlled Trials, Database of Abstracts of 
Reviews of Effects, National Health Service Economic 
Evaluation Database and PsycINFO were searched for 
studies published between 1 January 1990 and 28 April 
2017. Online supplementary file 2 provides a description 
of the search terms used in each database.
Manual searches
The reference list of the studies included in this review, 
as well as those of previous literature reviews on HRQoL 
across the full spectrum of dementia, will be searched to 
identify additional potentially relevant studies. The studies 
informing the model parameters in identified model-
ling studies will be considered for inclusion. Conference 
abstracts identified through the electronic searches will 
be screened and manuscripts of relevant abstracts will be 
manually searched for.
Study selection
ENDNOTE V.X7 (Thomson Reuters) will be used for 
reference management. Database results will be imported 
to ENDNOTE where duplicates will be removed by one 
reviewer (KW) based on title and first author name. 
Subsequently, two reviewers (FL and KW) will inde-
pendently assess the titles and abstract of the studies 
to determine whether full-text review is needed, with 
disagreement being resolved by a third reviewer (HW). 
Full text will be sought for potentially relevant studies and 
assessed for final inclusion by two reviewers (FL and KW) 
with disagreements being resolved by a third reviewer 
(HW). The full selection process will be presented in a 
flow diagram according to PRISMA guidelines.18
Data extraction
Two of the following reviewers (SM, EN, FL, AG and JW) 
will extract the data from the final set of studies onto a 
data extraction form (see online supplementary file 2) 
with disagreements being solved by a third reviewer. Two 
native or fluent speakers will review and extract the data 
for the non-English references. The following informa-
tion will be extracted:
 ► Study details: title, author, publication details, 
language of the study, countries of the study;
 ► Study design: aim of the study, type of study, type of 
analysis, duration, outcomes measured, instruments 
used to measure them, administration mode;
 ► Participant information: type of participant, setting, 
inclusion and exclusion criteria, sample size, sociode-
mographic information, self or proxy rating;
 ► Disease-specific information: type of dementia, level of 
severity, instrument used to measure level of severity;
 ► Outcomes: outcomes measured, time points meas-
ured, subgroup analysis conducted;
 o
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 ► Results: HRQoL of patients by disease severity, HRQoL 
of caregivers by disease severity of the patients (where 
studies report HRQoL using different instruments or 
report the same instrument in different ways, data will 
be extracted for each of them);
 ► Conclusions: author’s conclusions.
Risk of bias (quality) assessment
The Effective Public Health Practice Project ‘Quality 
assessment tool for quantitative studies’21 recommended 
by the Cochrane Public Health Group will be used to 
assess the quality of the studies included in this review 
as it covers a wide range of study designs.22 Two of 
above-mentioned reviewers will independently assess 
each study and two native or fluent speakers will inde-
pendently assess the quality of each of the non-English 
studies.
Description of studies and analysis
We expect to find a diverse range of HRQoL measures for 
both patients and caregivers. The HRQoL measurements 
will be presented separately for patients and caregivers 
by instrument used and, if possible, graphically. When 
described, distinction will be made between the different 
types of dementia but with a special emphasis on AD, the 
most common cause. If possible, HRQoL will be reported 
for each stage of the disease and if the HRQoL was self-
rated or proxy rated informed by a caregiver or care/
research professional. Descriptive statistics of the results 
will be provided.
A narrative synthesis of all relevant studies will be 
provided discussing differences in HRQoL measure-
ments by instrument used to estimate it, type of dementia, 
disease severity, setting and describing study and partic-
ipants’ characteristics, results and author’s conclusions.
In case the study does not provide all the necessary data 
for our analysis, we will contact the authors of the studies 
included in this review to attempt to retrieve it.
If feasible, a meta-analysis of the findings will be 
conducted.
dIsCussIon
This systematic literature review will identify and synthe-
sise the measurements of QoL, both preference and 
non-preference based, for patients across the full spec-
trum of dementia from MCI, predementia and dementia 
to end of life and their caregivers. HRQoL is increasingly 
seen as an important outcome in dementia research, and 
this level of detailed measurements of HRQoL will be 
useful and help to better inform disease progression and 
cost-effectiveness models of dementia.
We will present HRQoL measurements separately by 
disease type when the information is available. The main 
focus of our research is on AD, the most common cause 
of dementia, but given the lack of diagnostic accuracy 
and the recognised overlap between different causes of 
dementia, all causes of dementia will be considered.
Even though HRQoL as a measurement of the health 
status of individuals has been used since the second half 
of the 20th century, it was only in the 1990s that its use 
increased with the introduction of instruments such as 
EQ-5D-3L23 and SF-6D.24 As such, this review will include 
published studies on HRQoL since 1990. Furthermore, 
no languages or geographic restrictions were applied to 
the searches.
In conclusion, the results of this review could inform 
models assessing interventions on dementia for both 
patients and their caregivers by providing information 
about patient’s and caregiver’s perspective on treatment 
benefits. Additionally, this synthesis of HRQoL measure-
ments for dementia patients and their caregivers can help 
policy-makers better understand the impact of this stag-
gering clinical condition.
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